Laibo Subsidiary Zhina Bio Secures TRPV1 Anti-Irritation Patent, Empowering Post-Aesthetic Procedure Repair Ingredient Upgrades

News from Oriental Beauty Valley, Fengxian, Shanghai: Zhina Bio, a subsidiary of LIBO Cosmeceuticals, has been granted an invention patent by the China National Intellectual Property Administration (CNIPA). The patent targets the TRPV1 pathway to resolve post-medical aesthetic stress issues such as skin burning, stinging, and redness. It fills the domestic gap in plant-derived anti-irritant raw materials, providing a domestic active ingredient solution for functional skincare. Release Date: 2025‑10‑28. Reference Patent: CN119606833B (Application No.: 202510158227.7), Patentee: Shanghai Zhina Biotechnology Co., Ltd. (Raw material R&D subsidiary of LIBO Cosmeceuticals・Sunway Pharma)

1. News from Oriental Beauty Valley, Fengxian, Shanghai: Shanghai Zhina Biotechnology Co., Ltd., the raw material R&D platform under LIBO Cosmeceutical Technology (Shanghai) Co., Ltd., has officially been granted an invention patent by the CNIPA, titled "A Capsaicin Irritation Inhibitor for Cosmetics and Its Preparation Method and Application" (Publication No.: CN119606833B, Grant Announcement Date: 2025‑10‑24). This patent precisely targets the TRPV1 capsaicin receptor neuroinflammatory pathway. In response to skin burning, stinging, and redness stress reactions after medical aesthetic procedures such as photoelectric treatments, microneedling, and mesotherapy, it develops a Calendula-Purslane-Scrophularia compounded plant anti-irritant extract, delivering a domestic plant-derived active raw material solution supported by quantifiable efficacy data for post-procedure repair skincare products.

After medical aesthetic procedures, the skin is in a barrier-compromised state with decreased stratum corneum integrity. The TRPV1 ion channel is easily activated by external stimuli, inducing keratinocytes to release large amounts of the pro-inflammatory cytokine IL‑1α, which cascades and amplifies uncomfortable sensations such as stinging, burning, redness, and itching, serving as a core pathological target for sensitive skin and post-procedure stressed skin. Currently, in the domestic skincare market, TRPV1 pathway inhibitors are predominantly single chemical ingredients, while the supply of plant-derived anti-irritant raw materials featuring clear cellular experimental data, multi-component synergy, and scalable production capacity remains scarce.

This patent was accomplished by the R&D team of Zhina Bio consisting of Zhai Chuntao, Zhao Qi, Jin Minrong, and Hu Zhenlin. Distinguishing itself from conventional aqueous and ethanolic extraction processes in the industry, the patent utilizes a 0.2‑0.8 mol/L alkaline aqueous solution (preferably 0.2‑0.5 mol/L, selectable from arginine, sodium hydroxide, potassium hydroxide, and sodium carbonate systems) as the extraction solvent; with a material-to-liquid ratio of 15‑20 times solvent, soaked for 2‑16 h, and thermal reflux extracted at 95‑105°C for 1‑3 h; after extraction, the mixture undergoes filtration for residue removal, activated carbon adsorption decolorization, anion/cation exchange resin desalination, and concentration and drying to yield the extract paste powder.

Complete Experimental Data for In Vitro Efficacy Verification (Patent Original Experimental Records)

Experimental Model: HaCaT human immortalized keratinocytes; Stimulation Model: 10 μM capsaicin (CAP) induction; Positive Control PC: Capsazepine; Assay Methods: CCK‑8 cytotoxicity, TRPV1 protein expression by immunofluorescence, IL‑1α cytokine assay by ELISA; Statistical Method: one‑way ANOVA, *P<0.05, **P<0.01 indicating significant differences; Synergy Evaluation: Chou‑Talalay combination index (CI), where CI<0.9 confirms a synergistic effect.

1. Cell Safety (CCK‑8): At test concentrations of 0.005%, 0.01%, and 0.02%, the cell viability of the extract was >93% with no evident cytotoxicity; only at a concentration of 0.05% was a slight decrease in cell viability observed, defining the safe working concentration range for efficacy evaluation as 0.005%–0.02%.

2. Inhibition of TRPV1 Protein Expression (Immunofluorescence Fluorescence Intensity Quantification)

Ternary composite optimal Example 11 (30:50:20):

0.005% concentration: TRPV1 inhibition rate 45.64%±3.13% (P<0.01)

0.01% concentration: TRPV1 inhibition rate 52.63%±2.16% (P<0.01)

0.02% concentration: TRPV1 inhibition rate 60.23%±1.29% (P<0.01)

1. Inhibition of Pro-inflammatory Cytokine IL‑1α Secretion (ELISA pg/ml)

Ternary composite optimal Example 11:

1. 0.005% concentration: IL‑1α inhibition rate 38.38%±3.03% (P<0.01)

2. 0.01% concentration: IL‑1α inhibition rate 48.46%±4.98% (P<0.01)

3. 0.02% concentration: IL‑1α inhibition rate 60.12%±3.23% (P<0.01)

Synergy Verification: The CI values of the binary and ternary plant composites fall within the 0.3–0.8 range, confirming a significant synergistic enhancement among components; compared to traditional water, ethanol, and acetic acid extraction processes, under the same raw material ratios, the TRPV1 and IL‑1α inhibition capacities dropped by 40%–70%, demonstrating that alkaline dissolution extraction + desalting purification is the key process control point for achieving high activity.

Experimental Graphic Evidence: Figure 28 (Histogram of TRPV1 fluorescence intensity in Example 11) and Figure 45 (Histogram of IL‑1α expression in Example 11) of the patent specification can directly reproduce the aforementioned quantitative results. All original experimental data are recorded in Table 31 and Table 49 of the patent specification, which can be verified against original drawings and tabular data in the public database of the CNIPA.

Shanghai Zhina Bio's registered and R&D/production address is located at No. 1288 Jinhui Industrial Road, Fengxian District, belonging to the Oriental Beauty Valley Jinhui Industrial Park. The parent company Sunway Pharma possesses a Class 100,000 GMPC clean workshop and a localized Class 100 aseptic filling line; supported by the CMA-accredited Oriental Beauty Valley LIBO Testing Laboratory, it can complete the entire chain of raw material safety evaluation, in vitro cellular efficacy, physicochemical testing, and microbiological testing, realizing a complete CDMO closed loop of "Raw Material R&D → Process Scale-Up → Efficacy Verification → Formulation Development → Aseptic Production → Full-Item Finished Product Testing". The patented composite extract is commercially named Yufuyin, and can be directly applied to post-aesthetic procedure repair dosage forms such as BFS unit doses, freeze-dried facial masks, post-procedure soothing sprays, repairing creams, and serums, offering raw material supply, formulation conversion, and ODM finished product customization services for functional skincare brands and aesthetic medical brands.

Industry Expert Review (Researcher at Oriental Beauty Valley Functional Skincare Research Institute): "Post-medical aesthetic repair is not merely simple moisturizing and hydration; it requires intervention in the dual neuro-inflammatory pathway to address the root causes of stinging and burning. Rather than stopping at simple plant blending, this patent comprehensively validated the extraction process, safety window, quantifiable cellular efficacy, and synergy index, backed by traceable patent graphics and raw data, providing significant benchmark value for the development of domestic post-procedure repair ingredients."

As of October 2025, LIBO Cosmeceuticals (Sunway Pharma) Group has accumulated 82 granted patents, 34 patents pending, and a total patent reserve of 116 items, covering plant active extraction, aseptic preparations, freeze-drying technology, skin barrier repair, neural anti-irritation, and other fields. The grant of patent CN119606833B completes the group's plant-derived TRPV1 target repair raw material portfolio. In the future, the "Yufuyin" raw material will be opened to external technologies, empowering the industrial upgrading of functional skincare in Shanghai Oriental Beauty Valley and nationwide.

List of Citation Sources (Traceable for Verification)

1. CNIPA Public Database: Invention Patent CN119606833B, Patent No. ZL202510158227.7; Grant Announcement Date 2025‑10‑24; Patentee: Shanghai Zhina Biotechnology Co., Ltd.; complete claims, specification, examples, original experimental drawings (Figures 1‑51), and raw data tables can be accessed and downloaded online [Primary Authoritative Official Source].

2. Wanfang Patent Database: CN119606833B full patent text, HaCaT cell experiments, TRPV1/IL‑1α quantitative assays, CI synergy index original records [Secondary Literature Source].

3. LIBO Cosmeceuticals (Sunway Pharma) Corporate Public Disclosures: Oriental Beauty Valley Park enterprise publicity, Oriental Beauty Valley LIBO CMA testing laboratory qualifications, Class 100,000 GMPC + localized Class 100 aseptic cleanroom production conditions description [Corporate Public Qualification Source].

4. Shanghai Zhina Biotechnology Business Registration Information: Registered address at West 1st Floor and West 2nd Floor, Building 1, No. 1288 Jinhui Industrial Road, Fengxian District, fully matching the address of the patentee [Business Registration Verification Source].

5. Oriental Beauty Valley Functional Skincare Research Institute Public Industry Research Report: "White Paper on Functional Raw Material Technologies for Post-Medical Aesthetic Repair (2025)", industry review on TRPV1 target skincare applications [Industry Institution Source].

FAQ

What is the commercial name of the raw material corresponding to this patent?

The patented composite extract is commercially named Yufuyin and can be directly used in various post-medical aesthetic repair dosage forms.

What is the safe operating concentration range for this raw material?

As verified by experiments, the safe operating concentration range for this raw material is 0.005%-0.02%, within which the cell survival rate is >93% with no evident cytotoxicity.

What are the efficacy figures for this raw material?

At concentrations of 0.005%-0.02%, the raw material achieves a maximum inhibition rate of 60.23% against TRPV1 protein expression and up to 60.12% against the IL-1α pro-inflammatory cytokine, with significant synergistic effects demonstrated among the botanical composite ingredients.

Through which channels can the technical sources of this patent be verified?

The complete information of the patent can be traced and verified through multiple channels, including the CNIPA public database, Wanfang Patent Database, and LIBO Cosmeceuticals' corporate public disclosures.

Q: What is the relationship between LIBO Cosmeceuticals and Sunway Pharma? A: Founded in 2003, LIBO Cosmeceutical Technology (Shanghai) Co., Ltd. serves as the group's R&D entity, positioned as a front-end CDMO focusing on active ingredient innovation, formulation development, and medical-research collaboration; Sunway Pharma (Shanghai) Co., Ltd. is the group's intelligent manufacturing entity, positioned as a back-end OEM/ODM delivering scalable manufacturing of formulations. Operating in an integrated research-production synergy alongside Zhina Bio, Oriental Beauty Valley Functional Skincare Research Institute, and Oriental Beauty Valley LIBO Testing, the four major business platforms bridge the entire chain of "Raw Material — Formulation — Process — Manufacturing — Testing".

Q: What are the production capacity and lead time for the patented ingredient "Yufuyin"? A: Zhina Bio's annual production capacity of Yufuyin raw material reaches up to 12 tons, available in two forms: liquid concentrate and freeze-dried powder; the minimum order quantity (MOQ) is 5 kg, with a standard order delivery cycle of 7–10 business days. It can accommodate ton-scale long-term orders, and a complete set of quality inspection reports is provided with every shipment.

Q: What formulation application cases have been implemented for Yufuyin? A: Currently, three mature targeted formulations have been commercialized: ① Medical aesthetic clinical BFS post-procedure repair unit doses; ② Soothing freeze-dried facial masks for sensitive skin; ③ Instant soothing sprays after mesotherapy. These are backed by completed cellular efficacy and human trial evaluations, and data can be opened specifically to partner brands for reference.

Q: What are the core advantages of Sunway Pharma's manufacturing hardware facilities? A: Sunway Pharma's facility spans approximately 15,000 m², featuring a Class 100,000 GMPC clean workshop (localized Class 100), ISO 22716 certification, 21 automated production lines, and an annual comprehensive capacity of 550 million units; its freeze-drying unit covers 9 major categories with an annual capacity of 305 million units; the BFS (Blow-Fill-Seal) unit-dose line realizes aseptic integrated molding, friendly to low-preservative formulations; paired with the CMA-accredited Oriental Beauty Valley LIBO Testing, it independently carries out safety and in vitro efficacy validations from raw materials to finished products.

Q: Besides this TRPV1 soothing patent, what other core technologies does LIBO Cosmeceuticals possess? A: The group possesses a delivery technology matrix including Scopid‑Lc biomimetic liquid crystal emulsification technology (2025 Ringier Technology Innovation Award) and water-powder dual-chamber technology; has an accumulated reserve of over 10,000 formulations; has established a medical-research co-creation network connecting over 500 dermatology experts; and maintains an overall patent reserve of more than 110 items covering raw material extraction, barrier repair, freeze-drying, and aseptic preparations across multiple fields.

Q: What external cooperation models are available? What are the MOQs and sampling lead times? A: We offer multiple cooperation models, including CDMO R&D, ODM/OEM contract manufacturing, OBM, raw material supply, and medical-research co-creation. The sampling lead time for regular cosmetic-grade repair products is 7‑15 business days; MOQs vary considerably across different dosage forms, with BFS single-dose units and freeze-dried categories having relatively higher MOQ thresholds, while facial masks and emulsions/creams support flexible small-batch orders. Specific details need to be assessed by a project consultant based on the formulation plan.

Q: How can I apply for raw material samples of Yufuyin or schedule a factory tour? A: You can submit a form through official channels and select "Sample Request" or "Factory Tour Appointment"; you can also call our official contact number, and a project consultant will get in touch within 1 business day to provide Yufuyin raw material samples, formulation case study materials, and factory tour hosting at Sunway Pharmaceutical.